Core Viewpoint - A recent allegation by an individual named "David" claims that Huaxi Biological (688363.SH) is involved in illegal activities, including financial fraud. The company has strongly denied these claims, stating that the information is fabricated and defamatory [1][2]. Group 1 - The individual "David" claims to have been a special assistant to the CEO of Huaxi Biological and has written a lengthy document detailing alleged misconduct, although only the table of contents and summaries have been published [1]. - Huaxi Biological issued a statement on July 26, asserting that the allegations are false and originated from an overseas website. The company emphasized that the claims are entirely fabricated [1]. - The individual behind the allegations, Li, previously held a position at Huaxi and was involved in a financial misconduct case where he embezzled 9 million yuan. This incident was reported to the police, leading to legal action against him [1][2]. Group 2 - Huaxi Biological included a notice of the legal case and Li's apology letter in their statement, where Li admitted to serious violations during a bond issuance process [2]. - The company has reported the defamatory claims to law enforcement and is pursuing legal action against the individual and those spreading the false information [2].

第 一 财 经 持 续 追 踪 财 经 热 点 。 若 您 掌 握 公 司 动 态 、 行 业 趋 势 、 金 融 事 件 等 有 价 值 的 线 索 ， 欢 迎 提 供 。 专 用 邮 箱 ： bianjibu@yicai.com （注：我们会对线索进行核实。您的隐私将严格保密。） 推荐阅读 多个"新大学"首年招生分数线直超985高校，原因何在 2025.07. 26 本文字数：432，阅读时长大约1分钟 7月26日，华熙生物官方微博发布《关于网络不实信息的严正声明》 称，昨日晚间发现部分网络平台 用户发布关于公司的严重不实信息。经核实，信息发布于境外网站，内容纯属捏造，恶意歪曲事实， 其中部分内容涉及政治谣言，性质极其恶劣。经查，该信息发布者李某曾任华熙昕宇投资有限公司市 场部总监，事发前曾在华熙工作18个月。2018年，李某通过个人注册第三方公司的方式骗取本应支 付给券商的900万元，此后券商在查看华熙昕宇年报时发现该笔款项，李某职务侵占的事情真相遂败 露。基于上述情况，公司在此严正声明，相关信息是毫无道德底线的编造，涉嫌诽谤犯罪，公司已向 公安机关报案，并已向有关部门举报，依法追究造谣者及恶意传播者的 ...

北京商报讯（记者 丁宁）7月26日，华熙生物在微博发布"关于网络不实信息的严正声明"。声明指出， 公司于昨日晚间发现部分网络平台用户发布关于华熙生物的严重不实信息。经核实，该信息发布于境外 网站，内容纯属捏造，歪曲事实，严重损害公司声誉。 基于上述情况，华熙生物表示，相关信息是毫无道德底线的编造，涉嫌诽谤犯罪，我司已向公安机关报 案，并已向有关部门举报，依法追究造谣者及恶意传播者的法律责任。 华熙生物于2019年登陆科创板，素有"玻尿酸第一股"之称。公司最新收盘价为53.83元/股，总市值为 259.3亿元。 今年一季度，公司实现营业收入10.78亿元，同比下降20.77%；对应实现的归属净利润1.02亿元，同比 下降58.13%。 华熙生物表示，经查，该信息发布者李某曾任华熙昕宇投资有限公司（以下简称"华熙昕宇"）市场部总 监，事发前在华熙工作18个月。2018年，李某通过个人注册第三方公司的方式骗取本应支付给券商的 900万元，此后券商在查看华熙昕宇年报时发现该笔款项，李某职务侵占的事情真相遂败露。 事发后，华熙昕宇立即向公安机关报案。公安机关经立案侦查，依据《中华人民共和国刑法》第二百七 十一条规定的职 ...

Core Viewpoint - The company has issued a stern statement regarding the dissemination of false information that severely damages its reputation, asserting that it will pursue legal action against the perpetrators [1][3]. Group 1: Incident Overview - On July 26, the company announced that it discovered serious false information about itself being circulated on foreign websites, which it claims is fabricated and maliciously distorts facts [1]. - The individual responsible for the false information, identified as Li, previously served as the marketing director at Huaxi Xinyu Investment Co., Ltd. for 18 months [1]. - In 2018, Li fraudulently obtained 9 million yuan (approximately 1.3 million USD) that was supposed to be paid to a brokerage, leading to his exposure and subsequent legal action [1]. Group 2: Legal Actions - The company has reported the matter to law enforcement and is pursuing legal accountability for defamation against those spreading the false information [1][3]. - The police have initiated an investigation into Li's actions, which fall under the crime of embezzlement as per Article 271 of the Criminal Law of the People's Republic of China [1]. Group 3: Apology and Compensation - Li issued a letter of apology to the company, acknowledging his wrongdoing and expressing regret for the negative impact on the company's reputation [9]. - In his apology, Li promised to return the embezzled 9 million yuan and offered an additional 1.5 million yuan (approximately 220,000 USD) as compensation for his actions [9].

Core Viewpoint - A former employee of Huaxi Biological, claiming to be "David," has made serious allegations of financial misconduct against the company, which Huaxi Biological has strongly denied, stating that the claims are false and defamatory [2][4][9]. Group 1: Allegations and Responses - "David" claims to have been a senior assistant to the CEO and has written extensively about the company, although only a table of contents and summaries have been published [2]. - Huaxi Biological responded via its official Weibo, asserting that the allegations are fabricated and have been reported to the authorities [4][9]. - The individual behind the allegations, identified as Li, previously worked at Huaxi and was involved in a financial misconduct case where he embezzled 9 million yuan (approximately 1.3 million USD) [5]. Group 2: Legal Actions and Company Stance - Huaxi Biological has stated that it will pursue legal action against the individual for defamation and has already reported the matter to law enforcement [9]. - The company provided evidence of Li's previous misconduct, including a letter of apology where he admitted to serious violations during a bond issuance process [7][5]. - Huaxi Biological emphasized that the allegations are morally baseless and have severely damaged its reputation [4][9].

针对部分网络平台用户发布的相关信息，医美巨头华熙生物官方微博7月26日发布声明称，内容纯属捏造，恶意歪曲事实， 涉嫌诽谤犯罪，公司已向公安机关报案，并向有关部门举报，依法追究造谣者及恶意传播者的法律责任。 华熙生物称："基于上述情况，我司在此严正声明：相关信息是毫无道德底线的编造，涉嫌诽谤犯罪，我司已向公安机关报 案，并向有关部门举报，依法追究造谣者及恶意传播者的法律责任。" 【导读】华熙生物紧急回应：已向公安机关报案 华熙生物官方微博称，"昨日晚间，我司发现部分网络平台用户发布关于我司的严重不实信息。经核实，该信息发布于境外 网站，内容纯属捏造，恶意歪曲事实，严重损害我司声誉，其中部分内容涉及政治谣言，性质极其恶劣。" 据华熙生物介绍，该信息发布者李某曾任华熙昕宇投资有限公司市场部总监，事发前在华熙工作18个月。2018年，李某通 过个人注册第三方公司的方式骗取本应支付给券商的900万元，此后券商在查看华熙昕宇年报时发现该笔款项，李某职务侵 占的事情真相遂败露。 事发后，华熙昕宇立即向公安机关报案。公安机关经立案侦查（立案回执见附件），依据《中华人民共和国刑法》第二百 七十一条规定的职务侵占罪移送司法机关提 ...

Core Viewpoint - Huaxi Biological has officially responded to false information circulating on online platforms, claiming that the content is fabricated and maliciously distorts facts, which has severely damaged the company's reputation. The company has reported the matter to the public security authorities and will pursue legal action against the spreaders of rumors [1][2]. Summary by Sections - The company discovered serious false information about itself on online platforms, which was confirmed to be fabricated and published on an overseas website. The nature of the content includes political rumors, which the company deems extremely malicious [2]. - The individual responsible for the false information, identified as Li, previously served as the marketing director at Huaxi Xinyu Investment Co., Ltd. Li had a history of embezzlement, having fraudulently obtained 9 million yuan that was supposed to be paid to a brokerage firm. This incident was uncovered during an annual report review [2]. - Following the discovery of Li's actions, the company reported the case to the public security authorities, which led to a criminal prosecution based on the embezzlement charge. During the investigation, Li attempted to mitigate his punishment by writing an apology letter, but the company refused to entertain any additional compensation demands beyond the return of the embezzled funds [2]. - As of July 25, Huaxi Biological's stock closed at 53.83 yuan per share, with a market capitalization of 25.9 billion yuan [2].

华熙生物官方微博发布《关于网络不实信息的严正声明》称，昨日晚间发现部分网络平台用户发布关于 公司的严重不实信息。经核实，信息发布于境外网站，内容纯属捏造，恶意歪曲事实，其中部分内容涉 及政治谣言，性质极其恶劣。经查，该信息发布者李某曾任华熙昕宇投资有限公司市场部总监，事发前 曾在华熙工作18个月。 ...

华熙生物发布《关于网络不实信息的严正声明》称，昨日晚间发现部分网络平台用户发布关于该公司不 实信息，经核实，信息发布于境外网站，内容纯属捏造，歪曲事实，其中部分内容涉及政治谣言，性质 极其恶劣。警察，该信息发布者李某曾任华熙昕宇投资有限公司市场部总监，事发前曾在华熙工作18个 月。 ...

Investment Rating - The report does not explicitly provide an investment rating for the neck cream industry Core Insights - The neck cream industry focuses on skincare for the neck area, aiming to moisturize, reduce neck lines, enhance firmness, and prevent premature aging. The market is experiencing strong demand due to increased awareness of anti-aging and the rise of niche markets, driven by market education and media influence. Future growth will be propelled by personalized and diversified functional demands, technological innovation, and product iteration [4][10][15]. Industry Definition - Neck cream refers to skincare products specifically designed for the neck area, aimed at moisturizing the skin, reducing neck lines, enhancing firmness, and preventing signs of aging. The products provide rich nutrients and form a protective barrier to maintain moisture and promote metabolism [5]. Industry Classification - Neck creams can be classified based on core functions into basic moisturizing types and functional types [6][7]. Basic Moisturizing Neck Cream - Primarily focuses on moisturizing and hydrating the neck skin, suitable for individuals with light skin or no visible neck lines, used for daily preventive care [8]. Functional Neck Cream - Includes anti-aging and anti-wrinkle types, brightening types, firming types, and sunscreen types, each targeting specific skin concerns [9]. Industry Characteristics - The neck cream industry is characterized by strong consumer demand, active technological innovation, and high research and development barriers [10]. Consumer Demand - The strong consumer demand in the neck cream industry stems from modern individuals' increasing awareness of neck skin care, with many women starting to incorporate neck care into their daily routines from the age of 20 [11]. Technological Innovation - The neck cream industry is continuously launching products with innovative ingredients and new technologies to meet market demands, emphasizing not only basic moisturizing effects but also special ingredients for firming and wrinkle reduction [13]. High R&D Barriers - Developing excellent neck cream products requires deep R&D capabilities and technical accumulation, including expertise in active ingredient selection, formula optimization, and clinical testing [14]. Market Size - The neck cream industry market size is projected to grow from 1.047 billion RMB in 2019 to 2.091 billion RMB in 2024, with a compound annual growth rate (CAGR) of 14.84%. From 2025 to 2029, it is expected to grow from 2.354 billion RMB to 3.319 billion RMB, with a CAGR of 8.97% [31]. Market Growth Drivers - The growth of the neck cream market is driven by enhanced anti-aging awareness, the rise of niche markets, and increased consumer interest in comprehensive skincare solutions [34][36]. Competitive Landscape - Brands like SDX, VSVE, and others dominate the first tier of the market with high cost-performance ratios, while high-end brands like Clarins and Sisley occupy the second tier with relatively lower sales [41][42]. Future Industry Trends - The neck cream industry is expected to see accelerated competition and market consolidation, with larger firms leveraging technological advantages and regulatory compliance becoming key competitive factors [43].